Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial protein phosphatase 2C (PP2Cm) is a serine/threonine phosphatase located in the mitochondrial matrix, highly conserved among vertebrates, and especially expressed in the heart and brain. It regulates the mitochondrial permeability transition pore (mPTP), a non-selective channel in the inner mitochondrial membrane that opens in response to calcium overload, oxidative stress, or other signals, facilitating cell death or survival. PP2Cm deficiency increases sensitivity to calcium-induced mPTP opening, leads to cell death, and is required for normal cardiac and neural development[5][7]. While PP2Cm is a novel essential regulator, the pore-forming subunits of mPTP remain controversial, with candidates including the adenine nucleotide translocase, phosphate carrier, F-ATP synthase, and Cyclophilin D[1][4][6].
For Cyclosporin A: inhibition of Cyclophilin D, preventing conformational changes required for mPTP opening[4][3] - For hypothetical PP2Cm-targeting drugs: modulation of protein phosphorylation status to regulate mPTP sensitivity to calcium overload[5][7]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial protein phosphatase 2C (PP2Cm).